Olivier Rouvière

Olivier Rouvière

Auto-generated profile, based on publicly available information

Olivier Rouvière

Hospices Civils de Lyon, Hôpital Edouard Herriot, Department of Imaging, Lyon, 69003, France; INSERM, LabTAU, U1032, Lyon, 69003 , France; Université Lyon 1, Lyon, 69003, France

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in European Urology
Verified
Journal Article
Closed access
NMNicolas Mottet
Nicolas Mottet
JBJoaquim Bellmunt
Joaquim Bellmunt
MBMichel Bolla
Michel Bolla
EBErik Briers
Erik Briers
MCMarcus G. Cumberbatch
Marcus G. Cumberbatch
PCPhilip Cornford
Philip Cornford

10 February 2012 in European Radiology
Verified
Journal Article
Open access
PDF file
JBJelle O. Barentsz
Jelle O. Barentsz
JRJonathan Richenberg
Jonathan Richenberg
RCRichard Clements
Richard Clements
PCPeter Choyke
Peter Choyke
SVSadhna Verma
Sadhna Verma
JFJurgen J. Fütterer
Jurgen J. Fütterer
The aim was to develop clinical guidelines for multi-parametric MRI of the prostate by a group of prostate MRI experts from the European Society of Urogenital Radiology (ESUR), based on literature evidence and consensus expert opinion. True evidence-based guidelines could not be formulated, but a compromise, reflected by “minimal” and “optimal” requirements has been made. The scope of these ESUR guidelines is to promulgate high quality MRI in acquisition and evaluation with the correct indications for prostate cancer across the whole of Europe and eventually outside Europe. The guidelines for the optimal technique and three protocols for “detection”, “staging” and “node and bone” are presented. The use of endorectal coil vs. pelvic phased array coil and 1.5 vs. 3 T is discussed. Clinical indications and a PI-RADS classification for structured reporting are presented. Key Points • This report provides guidelines for magnetic resonance imaging (MRI) in prostate cancer. • Clinical indications, and minimal and optimal imaging acquisition protocols are provided. • A structured reporting system (PI-RADS) is described.

1 April 2017 in European Urology
Verified
Journal Article
Closed access
PCPhilip Cornford
Philip Cornford
JBJoaquim Bellmunt
Joaquim Bellmunt
MBMichel Bolla
Michel Bolla
EBErik Briers
Erik Briers
MSMaria De Santis
Maria De Santis
NMNicolas Mottet
Nicolas Mottet

1 January 2019 in The Lancet Oncology
Verified
Journal Article
Closed access
OROlivier Rouvière
Olivier Rouvière
PPPhilippe Puech
Philippe Puech
RRRaphaële Renard-Penna
Raphaële Renard-Penna
MCMichel Claudon
Michel Claudon
CRCatherine Roy
Catherine Roy
JWJochen Walz
Jochen Walz

1 June 2019 in European Urology
Verified
Journal Article
Open access
TBThomas Van Den Broeck
Thomas Van Den Broeck
RBRoderick C.N. van Den Bergh
Roderick C.N. van Den Bergh
NANicolas Arfi
Nicolas Arfi
TGTobias Gross
Tobias Gross
LMLisa Moris
Lisa Moris
NMNicolas Mottet
Nicolas Mottet
In men with prostate cancer (PCa) treated with curative intent, controversy exists regarding the impact of biochemical recurrence (BCR) on oncological outcomes. To perform a systematic review of the existing literature on BCR after treatment with curative intent for nonmetastatic PCa. Objective 1 is to investigate whether oncological outcomes differ between patients with or without BCR. Objective 2 is to study which clinical factors and tumor features in patients with BCR have an independent prognostic impact on oncological outcomes. Medline, Medline In-Process, Embase, and the Cochrane Central Register of Controlled Trials were searched. For objective 1, prospective and retrospective studies comparing survival outcomes of patients with or without BCR following radical prostatectomy (RP) or radical radiotherapy (RT) were included. For objective 2, all studies with at least 100 participants and reporting on prognostic patient and tumor characteristics in patients with BCR were included. Risk-of-bias and confounding assessments were performed according to the Quality in Prognosis Studies tool. Both a narrative synthesis and a meta-analysis were undertaken. Overall, 77 studies were included for analysis, of which 14 addressed objective 1, recruiting 20 406 patients. Objective 2 was addressed by 71 studies with 29 057, 11 301, and 4272 patients undergoing RP, RT, and a mixed population (mix of patients undergoing RP or RT as primary treatment), respectively. There was a low risk of bias for study participation, confounders, and statistical analysis. For most studies, attrition bias, and prognostic and outcome measurements were not clearly reported. BCR was associated with worse survival rates, mainly in patients with short prostate-specific antigen doubling time (PSA-DT) and a high final Gleason score after RP, or a short interval to biochemical failure (IBF) after RT and a high biopsy Gleason score. BCR has an impact on survival, but this effect appears to be limited to a subgroup of patients with specific clinical risk factors. Short PSA-DT and a high final Gleason score after RP, and a short IBF after RT and a high biopsy Gleason score are the main factors that have a negative impact on survival. These factors may form the basis of new BCR risk stratification (European Association of Urology BCR Risk Groups), which needs to be validated formally. This review looks at the risk of death in men who shows rising prostate-specific antigen (PSA) in the blood test performed after curative surgery or radiotherapy. For many men, rising PSA does not mean that they are at a high risk of death from prostate cancer in the longer term. Men with PSA that rises shortly after they were treated with radiotherapy or rapidly rising PSA after surgery and a high tumor grade for both treatment modalities are at the highest risk of death. These factors may form the basis of new risk stratification (European Association of Urology biochemical recurrence Risk Groups), which needs to be validated formally.

1 July 2017 in European Urology
Verified
Journal Article
Open access
NFNicola Fossati
Nicola Fossati
PWPeter-Paul M. Willemse
Peter-Paul M. Willemse
TBThomas Van Den Broeck
Thomas Van Den Broeck
RBRoderick C.N. van Den Bergh
Roderick C.N. van Den Bergh
YYYuhong Yuan
Yuhong Yuan
Steven JoniauSteven Joniau
Steven Joniau
There is controversy regarding the therapeutic role of pelvic lymph node dissection (PLND) in patients undergoing radical prostatectomy for prostate cancer (PCa). To systematically review the relevant literature assessing the relative benefits and harms of PLND for oncological and non-oncological outcomes in patients undergoing radical prostatectomy for PCa. MEDLINE, MEDLINE In-Process, Embase, and the Cochrane Central Register of Controlled Trials were searched up to December 2015. Comparative studies evaluating no PLND, limited, standard, and (super)-extended PLND that reported oncological and non-oncological outcomes were included. Risk-of-bias and confounding assessments were performed. A narrative synthesis was undertaken. Overall, 66 studies recruiting a total of 275,269 patients were included (44 full-text articles and 22 conference abstracts). Oncological outcomes were addressed by 29 studies, one of which was a randomized clinical trial (RCT). Non-oncological outcomes were addressed by 43 studies, three of which were RCTs. There were high risks of bias and confounding in most studies. Conflicting results emerged when comparing biochemical and clinical recurrence, while no significant differences were observed among groups for survival. Conversely, the majority of studies showed that the more extensive the PLND, the greater the adverse outcomes in terms of operating time, blood loss, length of stay, and postoperative complications. No significant differences were observed in terms of urinary continence and erectile function recovery. Although representing the most accurate staging procedure, PLND and its extension are associated with worse intraoperative and perioperative outcomes, whereas a direct therapeutic effect is still not evident from the current literature. The current poor quality of evidence indicates the need for robust and adequately powered clinical trials. Based on a comprehensive review of the literature, this article summarizes the benefits and harms of removing lymph nodes during surgery to remove the prostate because of PCa. Although the quality of the data from the studies was poor, the review suggests that lymph node removal may not have any direct benefit on cancer outcomes and may instead result in more complications. Nevertheless, the procedure remains justified because it enables accurate assessment of cancer spread.